FDA Expands Indications for Use of FibroScan® for Comprehensive Liver Management
FibroScan® by Echosens is now recommended for use in a larger patient population for diagnoses and management of liver disease
PARIS and WALTHAM, Mass., March 22, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has cleared expanded Indications for Use for screening with FibroScan®, the non-invasive liver management technology by Echosens.
"These updated Indications of Use are another proof point for screening with FibroScan to become commonplace in the clinical care pathway," said Jon Gingrich, CEO of Echosens.
The update furthers FibroScan® accessibility to more people, enabling physicians to identify those at risk of suffering adverse liver outcomes and connecting them with preventative care and treatment options.
The new clearance removes contraindications for pregnancy and active implants and includes the following:
FibroScan may aid the physician in determining the likelihood of cirrhosis and in the assessment of liver fibrosis and hepatic steatosis.
Designates FibroScan as a non-invasive aid for the clinical management, diagnosis, and monitoring of adult and pediatric patients with confirmed or suspected liver disease as part of an overall assessment of the liver.
The patient population has been expanded from "patients with liver disease" to "patients with confirmed or suspected liver disease."
Age has been removed as the first selection probe and exam-type step.
Measurement interpretation has been expanded to all physicians with appropriate training.
The removal of "estimates of" when referring to tissue stiffness.
"These updated Indications of Use are another proof point for screening with FibroScan to become commonplace in the clinical care pathway," said Jon Gingrich, CEO of Echosens. "Expanding the usage of FibroScan equipment to a larger patient population allows physicians to diagnose and manage suspected liver disease in earlier stages and provide a better quality of care."
The FibroScan device can be used to predict the risk of disease progression and decompensation, guide management decisions, evaluate response to treatment, and significantly reduce the need for a biopsy.
Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan®, the non-invasive solution for comprehensive management of liver health. For the past decade, FibroScan® has been recognized worldwide and validated by over 3,500 peer-reviewed publications and 160 international guidelines. Echosens has made FibroScan® available in over 100+ countries enabling millions of liver examinations worldwide. https://www.echosens.com/
Fluence, a global leader in evidence-based psychedelic therapy training, has announced a partnership with Metamorph AI, a pioneering AI technology company, to develop an AI-powered tool to enhance the training of psychedelic therapists.
We believe...
Next Gen Diagnostics (NGD) and a team at Vanderbilt University Medical Center (VUMC) today announced the results of a study reporting that comparison of the whole genome sequence (WGS) of bacterial pathogens obtained from surveillance of infants in a...
Community Healthcare Trust Incorporated (the "Company") today announced the release of its inaugural Corporate Sustainability Report for the year 2023. This comprehensive report highlights the Company's commitment to environmental stewardship,...
BJC HealthCare, one of the largest nonprofit health care organizations in the United States, and Encompass Health , the nation's largest owner and operator of inpatient rehabilitation hospitals, announce the opening of The Rehabilitation Institute of...
Cano Health, Inc. ("Cano Health" or the "Company"), a leading value-based primary care provider and population health company, today announced a global agreement with the Unsecured Creditors Committee representing the interests of the Company's...